Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study

Dalal, Rahul S.; Kallumkal, Govind; Cabral, Howard; Bachour, Salam; Barnes, Edward L.; Allegretti, Jessica R.

doi:10.1093/ibd/izad155

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another retrospective study, reporting data on 75 patients with UC receiving upadacitinib (all of whom previously exposed to biologics or small molecules, with 30% already exposed to tofacitinib), 64.0% were in steroid-free clinical remission between weeks 8 and 16; among 26 patients with available endoscopic evaluations, after a median of 23.3 weeks, 61.5% and 34.6% achieved endoscopic response and remission, respectively. Notably, tofacitinib-experienced patients were reported to have a comparable rate of steroid-free clinical remission compared to tofacitinib-naïve patients (p = 0.30) [35].…”

Section: Jak Inhibitors: Effectiveness In Real-world Studiesmentioning

confidence: 95%

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis

Cuccia,

Privitera,

Di Vincenzo

et al. 2024

JCM

View full text Add to dashboard Cite

Personalised medicine and the identification of predictors of the efficacy of specific drugs represent the ultimate goal for the treatment of ulcerative colitis (UC) in order to break the current therapeutic ceiling. JAK inhibitors are a new class of advanced therapies, orally administered, showing a good profile of efficacy and safety in both randomised controlled trials (RCTs) and real-world studies. Unfortunately, to date, it is not possible to draw the ideal profile of a patient maximally benefiting from this class of drugs to guide clinicians’ therapeutic choices. Baseline clinical activities and inflammatory biomarkers, as well as their early variation after treatment initiation, emerged as the main predictors of efficacy from post hoc analyses of RCTs with tofacitinib. Similar findings were also observed in the real-life studies including mainly patients with a history of pluri-refractoriness to biological therapies. At last, a few new biomarkers have been explored, even though they have not been validated in large cohorts. This paper provides a review of the current knowledge on clinical variables and biomarkers predicting response to JAK inhibitors in UC.

show abstract

Section: Jak Inhibitors: Effectiveness In Real-world Studiesmentioning

confidence: 95%

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis

Cuccia,

Privitera,

Di Vincenzo

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease

Yin,

El-Najjar,

Cordova

et al. 2024

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report

Xu,

Jiang,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Many patients with ulcerative colitis (UC) do not respond well to, or tolerate conventional and biological therapies. There is currently no consensus on the treatment of refractory UC. Studies have demonstrated that the selective Janus kinase 1 inhibitor upadacitinib, a small-molecule drug, is effective and safe for treating UC. However, no studies have revealed that upadacitinib is effective in treating refractory UC with primary nonresponse to infliximab and vedolizumab. CASE SUMMARY We report the case of a 44-year-old male patient with a chief complaint of bloody diarrhoea with mucus and pus, in addition to dizziness. The patient had recurrent disease after receiving mesalazine, prednisone, azathioprine, infliximab and vedolizumab over four years. Based on the endoscopic findings and pathological biopsy, the patient was diagnosed with refractory UC. In particular, the patient showed primary nonresponse to infliximab and vedolizumab. Based on the patient’s history and recurrent disease, we decided to administer upadacitinib. During hospitalisation, the patient was received upadacitinib under our guidance. Eight weeks after the initiation of upadacitinib treatment, the patient’s symptoms and endoscopic findings improved significantly. No notable adverse reactions have been reported to date. CONCLUSION Our case report suggests that upadacitinib may represent a valuable strategy for treating refractory UC with primary nonresponse.

show abstract

Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study

Cited by 4 publications

References 7 publications

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis

Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease

Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report

Contact Info

Product

Resources

About